- AI-designed ADHD drug sparked fresh investor interest in Bio Protocol’s BIO.
- Increase in volume indicates strong buying.
- The momentum for the token remains strong, but depends on sustained buying pressure.
AI Agent Designs ADHD Peptide in 24-hours For Under $1,500
The Bio Protocol’s CEO revealed that their team had created a new ADHD drug candidate in just 24 hours by using AI. Their AI system, PeptAI, not only designed the drug but it also tested it through various simulations and flagged real issues. Moreover, it also estimated that the first lab test would cost just $500-600.Bio was featured in Read Entire Article


English (US)